Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411785 | 0.83 | GRM2 (0.47) | GRM2TDO2MAPT | |
| SCHEMBL6521129 | 0.80 | CXCR2 (0.49) | GRM2MAPT | |
| SCHEMBL6516304 | 0.77 | GRM2 (0.48) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL3433545 | 0.71 | CA2 (0.44) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL7779461 | 0.67 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL7777653 | 0.64 | PTGS2 (0.48) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL6525915 | 0.63 | SLC9A1 (0.48) | MAPT | |
| SCHEMBL27816697 | 0.62 | CA2 (0.75) | PTGS2CA1CA2CA4CA7 | |
| P-Chlorobenzenesulfonamide SCHEMBL196556 | 0.61 | CA2 (1.00) | PTGS2CA1CA2CA4CA7 | |
| P-Chlorobenzenesulfonamide SCHEMBL31527679 | 0.61 | CA2 (1.00) | PTGS2CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060017-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-03-10 | — | — | US | claimed |
| US-20110060017-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060017-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNA5, CHRNB3 | PTGS2 1317/4885CA1 3520/4885CA2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.